{
    "symbol": "PSNL",
    "quarter": 1,
    "year": 2022,
    "date": "2022-05-04 23:44:06",
    "content": " But we have built into that also the ability to look for things like emerging resistance mutations and second primaries and so I think we can be much more informative if a pharma company has patients in a clinical trial and you have some patients responding and some not, I think we can provide much more detailed data on that than you would get from just a conventional small panel on the liquid biopsy side or from something that\u2019s just a -- an MRD test."
}